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Risk factors indicate the importance of oxidative stress during ovarian carcinogenesis. To
tolerate oxidative stress, cells activate the transcription factor Nrf2 (Nfe2l2), the master
regulator of antioxidant and cytoprotective genes. Indeed, for most cancers, hyperactivity
of Nrf2 is observed, and siRNA studies assigned Nrf2 as therapeutic target. However, the
cancer-protective role of Nrf2 in healthy cells highlights the requirement for an adequate
therapeutic window. We engineered artificial transcription factors to assess the role of
Nrf2 in healthy (OSE-C2) and malignant ovarian cells (A2780). Successful NRF2 up- and
downregulation correlated with decreased, respectively increased, sensitivity toward
oxidative stress. Inhibition of NRF2 reduced the colony forming potential to the same
extent in wild-type and BRCA1 knockdown A2780 cells. Only in BRCA1 knockdown A2780
cells, the effect of Nrf2 inhibition could be enhanced when combined with PARP inhibitors.
Therefore, we propose that this combination therapy of PARP inhibitors and Nrf2 inhibition
can further improve treatment efficacy specifically in BRCA1 mutant cancer cells without
acquiring the side-effects associated with previously studied Nrf2 inhibition combinations
with either chemotherapy or radiation. Our findings stress the dual role of Nrf2 in carcino-
genesis, while offering approaches to exploit Nrf2 as a potent therapeutic target in ovarian
cancer.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.element; ATF, artificial transcription factor; BER, base excision repair; CRISPR/Cas9, clus-
c repeats associated 9 protein; EOC, epithelial ovarian cancer; ER UPR, endoplasmatic retic-
logous recombination; KEAP1, Kelch like-ECH-associated protein 1; N4Py, ligand 1 of the
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MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 5 9e1 2 7 312601. Introduction cells without increasing adverse effects in healthy cells. PARPOxidative stress is a well-established risk factor for cancer
(Sosa et al., 2013). It reflects an imbalance between production
and detoxification of reactive oxygen species (ROS) and causes
oxidative damage to biomolecules, including DNA. The cell
has several defense mechanisms to protect itself against
oxidative stress, including antioxidants, DNA-repair enzymes
and the endoplasmatic reticulum unfolded protein response
(ER UPR). The latter response is activated when cells accumu-
late an overload of (ROS-induced) unfolded or misfolded pro-
teins, causing ER stress (Walter and Ron, 2011). Activation of
the ER UPR results either in an adaptive response, in which
protein synthesis is inhibited and protein folding capacity is
increased, or, when not sufficient to overcome the ER stress,
a pro-apototic response (Rutkowski et al., 2006; Walter and
Ron, 2011). Oxidative stress and the ER UPR can activate cyto-
protective responses mediated by the master regulator Nrf2
(NFE2L2, nuclear factor erythroid 2-like 2) (Cullinan et al.,
2003; Kansanen et al., 2012).
Normally, Nrf2 is present in the cytoplasm where it is
bound by Kelch like-ECH-associated protein 1 (Keap1). There,
Keap1 mediates the ubiquitination of Nrf2, whereupon Nrf2
is targeted to the proteasomes for degradation. When cells
are exposed to oxidative stress, the cysteine residues of
Keap1 become oxidized, resulting in disruption of the bind-
ing between Keap1 and Nrf2 (van der Wijst et al., 2014).
Nrf2 then translocates to the nucleus and binds to antioxi-
dant response elements (AREs). Binding of Nrf2 to AREs re-
sults in the transcription of its target genes (Malhotra et al.,
2010).
Not only healthy cells, but also various tumor cells,
including ovarian tumors (Konstantinopoulos et al., 2011;
Liao et al., 2012; Martinez et al., 2014), can acquire protection
against oxidative stress by constitutively activating Nrf2
(Bauer et al., 2013; Jiang et al., 2010; Stacy et al., 2006; Wang
et al., 2010). Thus the role of Nrf2 in carcinogenesis is bivalent
as Nrf2 has been assigned a protective, but also a cancer pro-
moting role (Lau et al., 2008). Therefore, activation of Nrf2 can
be exploited for cancer prevention (Cornblatt et al., 2007; Kou
et al., 2013), whereas inhibition of Nrf2 can be of therapeutic
value (Homma et al., 2009; Lister et al., 2011; Ma et al., 2012;
Singh et al., 2008). However, the cancer-protective role of
Nrf2 in healthy cells highlights the requirement for an
adequate therapeutic window. Therefore, insights into differ-
ential effects of Nrf2 modulation in normal and malignant
cells are essential to allow optimal exploitation of Nrf2 as
therapeutic target.
Combination therapies provide an opportunity to enhance
the therapeutic window of Nrf2 inhibition in cancer. Previ-
ously, the cytotoxic effects of Nrf2 inhibition could be further
enhanced by chemotherapeutics (Cho et al., 2008; Lister et al.,
2011; Wang et al., 2008), including cisplatin, or gamma-
radiation (Lister et al., 2011). However, inhibition of Nrf2 has
also been shown to exacerbate chemotherapy-inducedmyelo-
suppression (Cao et al., 2012). This side-effect severely limits
the use of such combination therapies. The combination
with PARP inhibitors may be an alternative strategy to
enhance the efficacy of Nrf2 inhibition preferentially in cancerinhibitors are small molecule inhibitors particularly effective
in tumors harboring a defect in double strand DNA (dsDNA)
break repair as they act by blocking single strandDNA (ssDNA)
repair by base excision repair (BER) (Banerjee and Kaye, 2011;
Fong et al., 2009). Interestingly, clinical trials have already
shown efficacy of PARP inhibitors as single agent in BRCA1
mutant ovarian tumors (Audeh et al., 2010; Fong et al., 2010).
Furthermore, the DNA damaging effect of PARP inhibitors
can be potentiated when combined with chemotherapy (as
reviewed in (Chen et al., 2013; Sessa, 2011)). In line with this,
we expect that Nrf2 inhibition combined with PARP inhibitor
treatment can enhance the DNA damaging effect of PARP in-
hibitors while diminishing the serious side-effects of
chemotherapeutics.
A unique approach to validate and obtain better insights
into the therapeutic potential of Nrf2 is the bivalent modula-
tion of NRF2 by artificial transcription factors (ATFs) targeted
to the NRF2 promoter region. ATFs contain a DNA-binding
domain, for example an engineered zinc finger protein (ZFP),
a transcription activator-like effector (TALE) protein or a clus-
tered regularly interspaced short palindromic repeats
(CRISPR) associated 9 (Cas9) protein (Gaj et al., 2013;
Gersbach and Perez-Pinera, 2014), fused to a transcriptional
activation or repression domain such as VP64 (four copies of
the viral protein VP16) or super KRAB domain (SKD), respec-
tively. ATFs have been successfully used to modulate gene
expression and study gene function in many disease models
both in vitro and in vivo (as reviewed in (Gaj et al., 2013;
Gersbach and Perez-Pinera, 2014; Sera, 2009)).
In the present study, we engineered ZFP-ATFs to modulate
NRF2 expression allowing investigation into the cancer-
preventive and therapeutic potential of Nrf2 in healthy (Nrf2
activation) and malignant ovarian epithelial cells (Nrf2 inhibi-
tion), respectively.We combined Nrf2 inhibition with PARP in-
hibitor treatment to further improve on the therapeutic
window of Nrf2 inhibition in cancer without acquiring the
side-effects associated with other previously studied combi-
nations such as chemotherapy and radiation.2. Materials and methods
2.1. Reagents
Ligand 1 of the iron(II) complex of the pentadentate ligand
N,N-bis(2-pyridylmethyl)-N-bis(2-pyridyl)-methylamine
(Fe(II)-1-N4Py), from now on abbreviated as N4Py, was synthe-
sized according to literature procedures and all characteriza-
tion data are in agreement with those reported (Li et al.,
2010). N4Py is a synthetic mimic of the metal-binding domain
of bleomycin. It acts as a catalyst that converts less-reactive
primary ROS in highly reactive secondary ROS. The main
advantage of using N4Py over directly adding ROS, such as
H2O2, to the culture medium, is the more constant and stable
production of ROS (Bjorkman and Ekholm, 1995; Li et al., 2010).
L-Buthionine sulphoximine (BSO), L-glutathione reduced
(GSH), GSH reductase, 5,5’dithiobis-(2-nitrobenzoic acid)
(DTNB) and NADPH were bought from SigmaeAldrich.
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The human ovarian carcinoma cell lines A2780 and SKOV3,
and the human embryonic kidney cell line HEK293T were ob-
tained from the ATCC. The temperature-sensitive, condition-
ally immortalized human ovarian surface epithelial (OSE-C2)
cells were kindly provided by Dr. Richard Edmondson (New-
castle University, UK) (Davies et al., 2003). All cell lines were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Lonza) supplemented with 10% FCS (Perbio Hyclone), 50 mg/
mL gentamycine sulfate (Invitrogen), 2 mM L-glutamine (Bio-
Whittaker). A2780, SKOV3 and HEK293T cells were cultured
at 37 C, whereas OSE-C2 cells were cultured at 33 C, both un-
der humidified conditions and 5% CO2.2.3. Engineering and delivery of artificial transcription
factors (ATFs)
The promoter region of NRF2 transcript variant 1 (NCBI-id:
NM_006164_4) surrounding its transcription start site (TSS)
was screened with the online tool www.zincfingertools.org
for potential target sites for engineering zinc finger proteins
(ZFPs) consisting of six fingers fused together to target a 18
bp DNA region (Mandell and Barbas, 2006). Six ZFPs, named
OX1-OX6 (Table 1), were selected based on predicted high af-
finity for its designed target region and uniqueness in the hu-
man genome, as confirmed by an NCBI BLAST search. ZFPs
were synthesized at Bio Basic Canada and were flanked by
SfiI restriction sites. Each ZFP was subcloned with SfiI restric-
tion enzymes into the pMX-IRES-GFP retroviral vector (Royer
et al., 2004), which contains an HA-tag, nuclear localization
signal (NLS) and either the transcriptional repressor (SKD),
the transcriptional activator (VP64) or no effector domain
(NoED). NRF2 transcript variant 1 cDNA was subcloned into
pMX-IRES-GFP with BamHI and NotI digestion enzymes. The
pMX-IRES-GFP (empty vector) and NRF2 cDNA constructs
functioned as controls. The OX2-SKD ATF, including its HA-
tag and NLS, was further subcloned into the lentiviral vector
pCDH-CMV-MCS-EF1-copGFP (System Biosciences) using
BamHI and NotI digestion.
In order to produce retroviral or lentiviral particles contain-
ing the ATFs, HEK293T packaging cellswere co-transfected us-
ing the calcium phosphate method with plasmids containing
the ATF, and viral packaging plasmids containing gag/pol
and the vesicular stomatitis virus G protein in a 3:2:1 ratio,
as described before (Huisman et al., 2013). Viral supernatantTable 1 e Zinc finger protein (ZFP) target sequences.
ZFP DNA strand Target region (50e30)
OX1 Sense TGA GTA CGT GAA AAA GAA
OX2 Antisense GCA AAC GGA GAA GCC CCT
OX3 Antisense GTG GGC CCT GCC TAG GGG
OX4 Antisense GCC GGG GTG GGG GGG GCT
OX5 Sense GCG GTA AAG TGA GAT AAA
OX6 Sense GCA ACT CCA AAT CAG GGAwas collected 48 h and 72 h post transfection and was used
in combination with 6 mg/ml polybrene (SigmaeAldrich) to
infect ovarian host cells. Three days post transduction, effi-
cient viral delivery was evaluated in host cells by the percent-
age of GFP-positive cells using flow cytometry (FACSCalibur,
BD Bioschiences) or by fluorescent microscopy (Leica DC300).
Only transductions resulting in 90% GFP positive cells were
included for analysis (Suppl. Figure 1A). In order to further
improve the delivery of lentiviral particles in A2780, cells
were superinfected and the top 25% GFP positive cells was
sorted with the MoFlo XDP (Beckman Coulter). By minimizing
the variation in GFP positivity, variation in the multiplicity of
infection (MOI) was reduced and any toxicity associated with
GFP expression would be equal in all conditions analyzed.
2.4. Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using the GeneJET RNA purification
kit (Thermo Scientific) according to the manufacturer’s proto-
col, including a 15 min DNaseI (Roche) treatment to avoid
gDNA contamination. 1 mg of total RNA was reverse tran-
scribed to cDNA using the RevertAid First Strand cDNA syn-
thesis kit (Thermo Scientific). qRT-PCR reactions were
performed in triplicate, containing 10 ng of cDNA, ABsolute
qPCR SYBR Green ROX Mix (Thermo Scientific) and gene-
specific primers (Table 2). qRT-PCR reactions were conducted
on the ViiA7 Real time PCR (Applied Biosystems) for
15 min at 95 C, followed by 40 cycles of 15 s at 95 C, 30 s at
60 C and 30 s at 72 C. GAPDH was used as housekeeping
gene. Data was analyzed using ViiA7 RUO software and rela-
tive expression compared to controls was calculated using
the DDCt method (Livak and Schmittgen, 2001).
2.5. Chromatin immunoprecipitation (ChIP)
Three days after transduction, binding of the ZFP to its
designed target region and histone modifications associated
with ZFP binding in this regionwere determined by ChIP. Cells
were fixed with 1% formaldehyde for 8 min at RT. After two
PBS washes, cells were lysed and subsequently sonicated for
8 min using a Bioruptor (Diagenode; 4 cycles of 3000 on, 3000
off). Sheared chromatin was collected by centrifugation for
10 min at 13.000 rpm at 4 C. 40 ml magnetic beads (Life tech-
nologies) were coated for 10min at RTwith 4 mg antibody (Rab-
bit IgG, Ab46540; HA-tag, Ab9110; H3K9me3, Ab8899 (Abcam);
H3K4me3, 07-473 (Millipore)). After washing the beads with
0.02% PBS-Tween, sheared chromatin of 25  104 cells was
added to the precoated magnetic beads and incubated O/N
at 4 C. The following day, unbound chromatin was collected
from the IgG control IP. All beads were washed 3 times with
PBS and DNA was eluted with elution buffer (1% SDS,
100 mM NaHCO3). Eluted DNA was RNase (Roche) treated un-
der high salt conditions O/N at 62 C. The next day, after a 1 h
incubation at 62 Cwith proteinase K (Thermo Scientific), DNA
was purified with the Qiagen Qiaquick PCR Purification kit
(Qiagen). qRT-PCR was performed using primers specific for
the OX2 and OX5 ZFP target region (Table 2) to determine rela-
tive enrichment of the HA-tag and histone marks in these re-
gions with the formula: percentage input ¼ 2(Ctinput e CtChIP)
* dilution factor * 100.
Table 2 e qRT-PCR Primer sequences.
Gene Forward primer (50e30) Reverse primer (50e30)
NRF2 ACACACGGTCCACAGCTCAT CCGTCGCTGACTGAAGTCAAAT
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Total protein extracts were collected in RIPA buffer (Thermo
Scientific). Nuclear (NER) protein extracts were obtained with
NE-PERNuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific). Protein quantification was performed with the DC
BioRad Protein Assay (BioRad). 70 mg protein was loaded on a
7% SDS-PAGE gel for the detection of BRCA1, whereas 20 mg
of NER protein was loaded on a 10% SDS-PAGE gel for the
detection of Nrf2. Blots were blocked for 1 h with 5% skimmed
milk in TBS-Tween. For detection, the following antibodies
were used: 1:200 rabbit anti-BRCA1 (C-20: sc-642, Santa Cruz
Biotechnology) 1:1000 rabbit anti-Nrf2 (Ab31163, Abcam),
1:1000 mouse anti-lamin B1 (clone L-5, Invitrogen), 1:5000
mouse anti-Actin (clone C4 MAB15O1, Millipore), and 1:2500
horseradish peroxidase-conjugated rabbit anti-mouse (P0260,
Dako) and swine anti-rabbit (P0217, Dako). Western blot signal
was generated with Pierce ECL Plus Western blot substrate
(Thermo Scientific) and detected with the Biorad ChemiDoc
MP imaging system (Biorad). Western blots were analyzed
with the Image Lab 5.0 software (Biorad).
2.7. Luciferase reporter assay
The promoter region ofNRF2 transcript variant 1 (288 toþ555
bp), containing both OX2 and OX5 target sites, was cloned into
pCpG-luc basic (promoterless) with BglII andHindIII restriction
sites. Two days after viral delivery of ATFs, host cells were
transiently transfectedwith lipofectamine LTX Plus (Life Tech-
nologies) in a 1:1:2 ratio of DNA (pCpG-luc NRF2 promoter):
plus reagent: lipofectamine LTX according to company’s in-
structions. Luciferase activity relative to empty vector was
determined 48 h post transfection with the Luciferase assay
system (Promega) on a Luminoskan ascent (Thermo Scientific).
For each condition, the total luciferase signal of 75,000 cells
was measured. Each experiment was performed in triplicate.
2.8. siRNA transfection
A2780 cells were reverse transfected with either BRCA1
esiRNA (EHU096311, SigmaeAldrich) or RLUC esiRNA(EHURLUC, SigmaeAldrich) using Lipofectamine RNAiMAX re-
agent (Life Technologies) in a 10:3 ratio of DNA: Lipofectamine
RNAiMAX according to the manufacturer’s protocol. For every
experiment, BRCA1 knockdown was confirmed by qRT-PCR.
FACS analyses (ROS production, cell death analysis, dsDNA
breaks) were performed 4 days after transfection. Cells that
were used for the MTS assay and colony forming assay
(CFA), were reverse transfected a second time 2 days after
the first transfection. TheMTS assaywas performed 2 days af-
ter the second transfection, the CFAwas seeded 1 day after the
second transfection.
2.9. Metabolic activity
0.35  104 OSE-C2 cells (empty, OX2-SKD, OX5-SKD, NRF2
cDNA) were seeded and 2  104 A2780 cells were (for the sec-
ond time) siRNA reverse transfected (empty RLUC/BRCA1
siRNA, OX2-SKD RLUC/BRCA1 siRNA) in 96-well plates. The
following day, OSE-C2 cells were treated for 48 h with
200 mM H2O2 (SigmaeAldrich), 5 mM N4Py or 0.1% DMSO as a
control. A2780 cells were treated for 24 h with 1 mM or 5 mM
of the PARP inhibitor olaparib (AZD-2281, KU-0059436,
Cayman Chemical) or 0.1% DMSO. After treatment, metabolic
activity wasmeasured by incubating the cells with CellTiter 96
Aqueous One Solution (Promega) for 3 h at 33 C (OSE-C2) or
37 C (A2780). The absorbance at 490 nm was measured using
a Biorad iMark microplate reader (Biorad) and subtracted with
the absorbance of cell-free medium. For every experiment,
triplicates were measured of each condition.
2.10. Total glutathione assay
A2780 cellswere treatedwith 0, 0.5, 1, 2 and 10mMBSO for 48h.
After treatment, cells were lysed in 5% trichloroacetic acid. Af-
ter a 5 min centrifugation at 10,000 g, the supernatant was
collected and diluted 1:15 in GSH buffer (0.125 M phosphate
buffer, 5mMEDTA,pH7.5). Total glutathione levelsweredeter-
mined in the resulting supernatant by the Tietze enzymatic
recycling assay (Tietze, 1969). Standards of knownGSHcontent
were serial-diluted in order tomake a standard curve. TheGSH
content of all samples was determined by reference to this
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1.5 mM DTNB and 0.25 U GSH reductase. Just before reading,
0.6mMNADPHwas added to start the reaction. The formation
of reducedDTNBwas followedat 405nmfor10minusingaVer-
saMax ELISA microplate reader (Molecular Devices). All stan-
dards and samples were measured in duplicate.
2.11. ROS production and cell death analysis
OSE-C2 cells (empty, OX2-SKD, OX5-SKD, NRF2 cDNA) or
A2780 cells (empty, OX2-SKD) were seeded in 12-wells plates.
The next day, when cells were about 80% confluent, treatment
was started. 24 h after starting treatment, floating cells were
collected and remaining cells were incubated with 5 mM Cell-
ROX Deep Red Reagent (Life Technologies) for 30 min at
33 C (OSE-C2) or 37 C (A2780) in complete medium. After 3
PBS washes, cells were harvested and combined with the
floating cells. All together, the cells were stained with 5 mg/
mL propidium iodide (PI) (SigmaeAldrich) in PBS. After a
10 min incubation at 4 C in the dark, PI fluorescence was
measured using the FL-3 channel and CellROX Deep Red fluo-
rescence was measured in the FL-4 channel of a FACScalibur
flow cytometer (Beckton Dickenson Biosciences). MFI of Cell-
ROX Deep Red and percentage PI positive cells was deter-
mined with Kaluza 1.3 software (Beckman Coulter).
2.12. dsDNA breaks
The amount of dsDNA damage induced by PARP inhibitor (co-)
treatment was analyzed using intracellular gH2AX staining
with FACS read-out as described before (Li et al., 2010). In
short, 12.5  104 A2780 cells (empty RLUC/BRCA1 siRNA,
OX2-SKD RLUC/BRCA1 siRNA) were seeded in 24-wells plates.
The next day, 1 mM olaparib or 0.1% DMSO treatment was
started. 24 h later, cells were harvested, fixed with 4% formal-
dehyde for 10min at 37 C and permeabilized in 90%methanol
for 30 min on ice. Cells were stained for 30 min at RT in the
dark with 1:50 rabbit anti-phospho-histone H2A.X (ser139)
conjugated Alexa Fluor 647 (20E3, Cell Signaling) and 100 mg/
ml RNase A (Qiagen) in 0.5% BSA/PBS. After washing the cells
with PBS, cells were stained with 5 mg/mL PI in PBS for
10min at 4 C in the dark. PI fluorescence wasmeasured using
the FL-3 channel and gH2AX fluorescence was measured in
the FL-4 channel of a FACScalibur flow cytometer (Beckton
Dickenson Biosciences). Cells in the subG1 population were
excluded from analysis of dsDNA breaks in early/non-
apoptotic cells. Percentage gH2AX positive cells in the early/
non-apoptotic cell population was determined with Kaluza
1.3 software (Beckman Coulter). The cutoff for a gH2AX posi-
tive cell was set based on a background level ofw3% positivity
in the empty vector, RLUC siRNA, 0.1% DMSO treated control.
2.13. Colony forming assay
A2780 cells (empty RLUC/BRCA1 siRNA, OX2-SKD RLUC/
BRCA1 siRNA) were treated for 24 h with 1 mM olaparib or
0.1% DMSO. After treatment, for every condition 1000 cells
were seeded in 6-wells plates containing fresh media. After
6e7 days, media was replaced by Coomassie brilliant blue
(Bio-Rad). The colony forming potential was determined bycounting the number of colonies (50 cells) using phase-
contrast microscopy. Data was generated in two independent
experiments, performed in duplicate.
2.14. Statistical analysis
Statistical tests were performed with Graphpad Prism 5 soft-
ware (GraphPad Software). All experiments were performed
at least three times, unless stated otherwise. Data was evalu-
ated by one-way, two-way analysis of variance and Student’s
t-test. Multiple comparisons of ANOVA were followed with
post-hoc Bonferroni. A p-value of<0.05 was considered statis-
tically significant. All data are presented as the mean  SEM.3. Results
3.1. NRF2 expression can be modulated by NRF2-
targeting ATFs in both healthy and malignant ovarian
epithelial cells
To modulate NRF2 expression, six different ZFP-SKD con-
structs (OX1-OX6), targeting the NRF2 promoter region
(Figure 1A), were engineered and virally delivered in three
ovarian cell lines: SKOV3, A2780 and OSE-C2. Successful deliv-
ery was confirmed by GFP FACS (Suppl. Figure 1A). OX2-SKD
and OX5-SKD modulated NRF2 expression about 1.5-fold and
up to twofold, respectively, in two out of three ovarian cell
lines tested (A2780 and OSE-C2) (Figure 1B). Unexpectedly,
expression of OX5 fused to the gene repressor SKD, resulted
in a twofold upregulation of NRF2 expression, in both A2780
and OSE-C2 cells. To find a possible explanation for this unex-
pected finding that OX5 when fused to a transcriptional
repressor (SKD) mediates activation, we performed a search
for transcription factor binding sites in MatInspector
(Genomatix). This search uncovered that binding of the tran-
scription factor YY2 partly overlaps (33%) with the OX5 ZFP
binding site. This opens up the possibility that YY2 binding
or function can be affected by an OX5-containing ATF.
To unravel the effects of OX2-SKD andOX5-SKD, validation
experiments were performed in OSE-C2 cells. ZFP binding to
its predicted target region was first confirmed by HA-tag
ChIP (Figure 2A). Binding competition with other gene regula-
tory proteins was assessed by analyzing the effects of ZFPs
only (NoED) and the ZFPs fused to the transcriptional activator
VP64. Successful viral delivery of all these constructs was
confirmed by GFP FACS (Suppl. Figure 1B). ZFPs without
effector domain did not affect NRF2 expression (Figure 2B).
OX2-VP64 showed a twofold upregulation, whereas OX5-
VP64 showed a 1.5-fold downregulation of NRF2 expression
(Figure 2B). So, VP64 ATFs showed the same level of modula-
tion as their SKD counterparts, but this time, in the opposite
direction. The opposite effects of OX2 and OX5 were
confirmed for the SKD fusions byNRF2 promoter luciferase re-
porter construct experiments (Figure 2C).
To gain more insights into the native chromatin state as
well as in the ATF-induced changes of the OX2 and OX5 tar-
geted region, a ChIP for the active histone mark H3K4me3
and repressive histone mark H3K9me3 was performed
(Figure 2D). These experiments indicated that the NRF2
Figure 1 e Modulation of NRF2 gene expression in normal and malignant ovarian epithelial cells by NRF2-targeting ATFs. (A) Schematic
overview of the NRF2 promoter region (transcript variant 1) containing the TSS (transcription start site, D1) and the target regions for the 6
engineered zinc finger proteins (ZFP OX1-OX6). Histone modifications associated with ATF OX2 and OX5 were determined in ChIP region
OX2-ChIP6 and OX5-ChIP5, respectively. CpGs are shown as vertical lines. (B) Relative NRF2 expression compared to empty vector control
upon retroviral delivery of NRF2-targeting ZFPs (OX1-OX6) fused to the transcriptional repressor SKD in SKOV3, A2780 and OSE-C2 cells.
Relative NRF2 expression of the NRF2 cDNA control has only been determined in OSE-C2 cells. Data is presented as mean ± SEM of at least
three independent experiments. *p< 0.05.
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mark H3K9me3, whereas theNRF2 upregulating ATF OX5-SKD
did not. Moreover, OX5-SKD associated upregulation of NRF2
did not result in an increase of the active histone mark
H3K4me3.
3.2. Gene-targeted modulation of NRF2 by ATFs results
in the modulation of downstream Nrf2 target genes
Before continuing to use the NRF2-ATFs as tool to study the
role of Nrf2 in ovarian carcinogenesis, they were further vali-
dated in healthy (OSE-C2) and malignant (A2780) ovarian cell
lines. Despite having about equal levels of GFP positive cells,
the average infection efficiency per cell was at least 10 fold
lower in A2780 compared to OSE-C2 cells (data not shown).
Therefore, in all subsequent experiments, average infection
efficiency in A2780 cells was further improved by using
lentivirally-superinfected, GFP sorted cells. Modulation of
NRF2 mRNA does not necessarily translate to functional
changes, as many post-translational factors regulate Nrf2
(van der Wijst et al., 2014), e.g. the cytoplasmic fraction of
Nrf2 can be bound by Keap1, and subsequently degraded.
Only when Nrf2 translocates to the nucleus, it can bind to
downstream target genes, but also here, the outcome is deter-
mined by the balance between repressive (e.g. Bach1, Src ki-
nases) and activating factors (Nrf2) (van der Wijst et al.,
2014). Moreover, some Nrf2 target genes are known to be
expressed only in certain tissues (Nakajima et al., 2011). A
quick screen on the expression of known Nrf2 target genesin OSE-C2 cells transduced to express NRF2 cDNA (Suppl.
Figure 2A) or treated with the ARE-inducer tBHQ (Suppl.
Figure 2B), indicated that GCLC, an enzyme involved in gluta-
thione synthesis, and the vitagene HMOX1, an enzyme
involved in heme catabolism, but not the phase 2 detoxifica-
tion enzyme NQO1, were potent downstream targets of Nrf2
in these cells. Subsequently, it was confirmed in OSE-C2 cells,
that the OX5-SKD mediated upregulation of NRF2 mRNA
(Figure 1B) resulted in activation of three well-known Nrf2
target genes (GCLC, HMOX1, OGG1) (Malhotra et al., 2010;
Singh et al., 2013). Indeed an increased expression of these
downstream genes was observed in OX5-SKD expressing cells
compared to empty vector: GCLC was upregulated by 1.7-fold,
HMOX1 by 2.7-fold and OGG1 by 1.6-fold (Figure 3A). Vice-
versa, in A2780 cells the OX2-SKD mediated downregulation
of NRF2 mRNA (Figure 1B) resulted in decreased nuclear Nrf2
protein levels (detected at 110 kDa, see Suppl. Figure 3, as
described before in (Lau et al., 2013; Malloy et al., 2013)) up
to about 80% (Figure 3B). This translated to repression of
Nrf2 target genes: GCLC was inhibited by 1.9 fold and HMOX1
by 1.7 fold (Figure 3C). Remarkably, despite the lack of robust
NRF2 mRNA inhibition in A2780 cells by OX2-SKD (Figure 1B),
themRNA inhibitionwas efficient enough to profoundly affect
nuclear Nrf2 protein levels (Figure 3B) and downstream genes
(Figure 3C). In addition to the NRF2mRNA, many other factors
can modulate the nuclear Nrf2 protein fraction (Chowdhry
et al., 2013; Khalil et al., 2014; van der Wijst et al., 2014). These
factors might explain the seemingly discrepancy between
NRF2 mRNA and Nrf2 protein inhibition by OX2-SKD.
Figure 2 e Validation of NRF2-targeting ATFs in normal ovarian epithelial cells. OSE-C2 cells were transduced to express OX2-and OX5-ZFP
fusions and both ATFs were validated (A) for ZFP binding; (B) for effector domain-specific effects; (C) for having a direct effect on the NRF2
promoter; (D) for epigenetic effects on their target region. (A) ZFP binding (HA-tag) in the OX2-ChIP6 region (left panel) and OX5-ChIP5
region (right panel) was validated by quantitative ChIP, IgG was used as negative control. (B) Relative NRF2 expression compared to empty vector
control upon retroviral delivery of NRF2-targeting ZFPs (OX1-OX6) fused to no effector domain (NoED), the transcriptional repressor SKD or
the transcriptional activator VP64. (C) Relative NRF2 promoter activity as measured by the luciferase activity of pCpG-NRF2 promoter-luciferase
of cells transduced to express OX2-SKD and OX5-SKD compared to cells expressing empty vector control. (D) Quantitative ChIP for an active
histone modification (H3K4me3), a repressive histone modification (H3K9me3) and IgG control of the OX2-ChIP6 region (left panel) and OX5-
ChIP5 region (right panel). Each bar represents the mean ± SEM of at least three independent experiments. *p< 0.05, ***p< 0.001.
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OX2-SKD in A2780 and OSE-C2 cells, this did not result in sig-
nificant repression of Nrf2 downstream genes in OSE-C2 cells
(Figure 3AeB), with the exception of the 1.7-fold reduction in
OGG1 mRNA levels (Figure 3A). This gives us a first hint that
healthy ovarian cells (OSE-C2) might be less sensitive toward
the effects of NRF2 inhibition compared to malignant ovarian
cells (A2780), which would agree with current literature that
cancer cells in general are often more dependent on a high
(Nrf2-induced) antioxidant capacity for their survival
(Gorrini et al., 2013b).
3.3. Cytoprotective effect of NRF2 might be partly
exerted by induction of ER UPR genes
Nrf2 is the master regulator of antioxidant and cytoprotec-
tive genes, and as such protects cells towards ROS. It isable to do so by activating downstream genes involved in
the stimulation of antioxidant production (GCLC, HMOX1)
and cytoprotection via the stimulation of the oxidative dam-
age DNA repair enzyme OGG1 (Figure 3A). We wondered
whether Nrf2 could also exert its cytoprotective function
by inducing an ER UPR. To this end, four genes involved in
this cytoprotective response were measured in OSE-C2 cells:
ERp72, HERP, Bip/GRP78, p58IPK. The expression of all these
ER UPR genes was increased in OX5-SKD expressing cells
compared to empty vector: ERp72 was upregulated by 1.7-
fold, HERP by 1.9-fold, Bip/GRP78 by 1.9-fold and p58IPK by
1.8-fold (Figure 4AeD). For all four genes a similar trend
was visible for NRF2 cDNA. On the other hand, NRF2 inhibi-
tion by OX2-SKD resulted in a trend towards reduction of
gene expression. The increased expression of ER UPR genes
in OX5-SKD expressing cells did not affect cell growth
(Suppl. Figure 4A).
Figure 3 e NRF2-targeting ATFs modulate the expression of known downstream Nrf2 target genes. The effect of NRF2-targeting ATFs on known
downstream Nrf2 target genes was assessed in healthy (OSE-C2) and malignant (A2780) ovarian cells. (A) Relative NRF2 expression of known
Nrf2 target genes (GCLC, HMOX1, OGG1) compared to empty vector control upon expression of the NRF2-targeting ATFs or NRF2 cDNA in
OSE-C2 cells. (B) Relative quantification of nuclear Nrf2 protein levels in NRF2-inhibiting ATF OX2-SKD expressing A2780 cells compared to
empty vector control. Insert: western blot against nuclear Nrf2 and Lamin B1 (nuclear loading control) containing nuclear protein lysates of A2780
empty vector and OX2-SKD expressing cells. (C) Relative expression compared to empty vector of known Nrf2 target genes (GCLC, HMOX1)
upon expression of the NRF2-inhibiting ATF OX2-SKD in A2780 cells. Data values are mean ± SEM of at least three independent experiments.
*p< 0.05, **p< 0.01, ***p< 0.001.
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the sensitivity toward ROS-induced damage
As shown above, gene-targeted modulation of NRF2 enabled
us to modulate downstream target genes involved in the pro-
tection against ROS-induced damage. Therefore, this is ex-
pected to influence endogenous ROS levels and as such
protect (Nrf2 upregulation) or sensitize (Nrf2 downregulation)
cells toward ROS-induced cell death. To determine the influ-
ence of ATF-mediated NRF2 modulation on ROS production
in OSE-C2 and A2780 cells, ROS levels were determined upon
exposure to a lethal dose of ROS (30 mM N4Py). In OSE-C2 cells
harboring upregulated NRF2 expression either induced by
OX5-SKD or NRF2 cDNA, ROS levels were reduced by about
20% compared to empty vector (Figure 5A). On the other
hand, OX2-SKD mediated downregulation of NRF2 expression
did not affect ROS production in these cells (Figure 5A). Simi-
larly, in A2780 cells, no increase in ROS production was
detected in NRF2 knockdown A2780 cells, as measured by
the Cell Rox Deep Red ROS probe (Figure 5B). The absence of
increased ROS production in NRF2 knockdown compared to
empty A2780 cells, even in the presence of 30 mM N4Py, might
be explained by the method of ROS induction. In order to test
whether less acute ROS induction wouldmake any difference,
A2780 cells were depleted of glutathione by BSO. Glutathione
depletion was confirmed in all tested BSO concentrations
(0.5e10 mM BSO) (Suppl. Figure 5A). Two days after BSO-
induced glutathione depletion, cell death (Suppl. Figure 5B)
and ROS production (Suppl. Figure 5C) were measured by
FACS. Neither cell death, nor ROS production was affected
by BSO treatment. Despite the absence of increased ROS pro-
duction in both OSE-C2 (Figure 5A) and A2780 cells
(Figure 5B) upon ATF-mediated NRF2 knockdown combined
with exposure to lethal ROS levels, a 1.5-fold higher level ofROS-production in these A2780 compared to OSE-C2 cells
was observed (Figure 5C).
Further experiments were conducted to reveal whether
the observed effects on endogenous ROS levels also affect
the sensitivity of OSE-C2 and A2780 cells toward ROS-
induced damage. To start with, the effect of sublethal ROS
levels, either induced by H2O2 or N4Py, was determined in
OSE-C2 cells that were transduced to express the NRF2-
ATFs. In cells expressing basal (empty vector) or lowered
(OX2-SKD) levels of NRF2, exposure to sublethal ROS levels
resulted in lower metabolic activity: 35% decrease upon
H2O2 and 26% decrease upon N4Py treatment compared to
untreated cells (Figure 4D). Cells with increased expression
of NRF2 were not significantly affected by the sublethal ROS
levels; upon treatment with H2O2, metabolic activity was
only slightly, but not significantly lowered in OX5-SKD
expressing cells (8%) compared to untreated cells, whereas
metabolic activity was unchanged in cells expressing NRF2
cDNA (0%). Treatment with N4Py equally, but not signifi-
cantly, affected OX5-SKD and NRF2 cDNA expressing cells
by reducing metabolic activity with 14% compared to un-
treated cells (Figure 5D). Similarly, when these cells were
exposed to lethal levels of ROS (induced by 30 mM N4Py),
cell death could be equally reduced by OX5-SKD and NRF2
cDNA (Figure 5E). Compared to empty vector, cells harboring
upregulated NRF2 expression showed a reduction of about
60% in cell death. So, the level of NRF2 upregulation (1.8-
fold for OX5-SKD vs 25-fold for NRF2 cDNA, Figure 1B) did
not significantly affect the protective effect of high NRF2
expression against (sub)lethal ROS levels in OSE-C2 cells
(Figure 5DeE). In these cells, OX2-SKD-mediated downregu-
lation of NRF2 expression did not result in increased sensi-
tivity toward ROS-induced cell death. On the contrary,
when A2780 cells were exposed to lethal ROS levels (induced
Figure 4 e NRF2-targeting ATFs modulate the expression of genes involved in the endoplasmatic reticulum unfolded protein response (ER UPR).
Normal ovarian epithelial cells (OSE-C2) were transduced to express NRF2-targeting ATFs or NRF2 cDNA. (AeD) Relative expression of genes
involved in the ER UPR (ERp72, HERP, Bip/GRP78, p58IPK) was determined. Data values are mean ± SEM of at least three independent
experiments. *p< 0.05, **p< 0.01, ***p< 0.001.
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expression increased the sensitivity toward ROS-induced cell
death almost twice; the percentage PI positive cells was
increased from 20% in empty vector control cells to 37% in
ATF-inducedNRF2 knockdown cells (Figure 5E). These results
indicate that upon ATF-mediated NRF2 inhibition the sensi-
tivity toward ROS-induced damage can be further increased
specifically in malignant ovarian cells (A2780), whereas the
effects on healthy ovarian cells (OSE-C2) seem to be un-
changed. Despite this, baseline sensitivity toward ROS-
induced cell death was lower in empty vector control A2780
compared to OSE-C2 cells: 20% versus 65% PI positive cells,
respectively. Therefore, ATF-mediated NRF2 knockdown
could not significantly alter overall sensitivity toward ROS-
induced cell death between both cell lines: 37% PI positive
cells in A2780 versus 55% in OSE-C2 cells (Figure 5C). This
finding highlights the importance of a combination therapy
to further improve on the cancer-selectivity of NRF2
inhibition.3.5. Gene-targeted downregulation of NRF2 by ATFs
improves the cytotoxic effect of PARP inhibitors in BRCA1
knockdown A2780 ovarian cancer cells
Extensive validation of the NRF2-targeting ATFs was per-
formed by (1) confirming binding to the target region
(Figure 2A); (2) confirming effective modulation at the
mRNA level (Figure 1B) (3) and protein level (Figure 3B); (4)
confirming functional downstream effects (Figures 3A, C
and 5AeE). This proved that NRF2-ATFs can be potent tools
to study the role of Nrf2 in ovarian carcinogenesis. Therefore,
this tool was used to unravel the potency of Nrf2 inhibition as
therapeutic target in ovarian cancer treatment. Moreover, it
was determined whether combining knockdown of NRF2
with PARP inhibitors could further improve the effect of
NRF2 inhibition on cancer cell growth of BRCA1 knockdown
ovarian cancer cells. As shown in Suppl. Figure 6, BRCA1 pro-
tein was almost completely knocked down 3 and 4 days after
transfection with BRCA1 siRNA compared to control RLUC
Figure 5 e Modulation of NRF2 by ATFs affects the sensitivity of normal and malignant ovarian epithelial cells against non-cytotoxic and
cytotoxic levels of ROS. OSE-C2 and A2780 cells were transduced to express NRF2-ATFs and were exposed to either non-cytotoxic (£10 mM
N4Py, 200 mMH2O2) or cytotoxic (30 mMN4Py) levels of ROS. The effect on ROS production compared to 0.1% DMSO control treatment was
determined after a 24 h exposure to 30 mM N4Py in OSE-C2 (A) and 10 mM or 30 mM N4Py in A2780 (B) cells. (C) For a direct comparison
between both cell lines, the absolute ROS production in OSE-C2 and A2780 cells was determined after a 24h treatment with 30 mM N4Py. (D)
OSE-C2 cells were exposed to either a bolus of 200 mMH2O2, 5 mMN4Py or no treatment. After 2 days, metabolic activity was measured by MTS
and compared to no treatment of the same cell line. (E) OSE-C2 and A2780 cells were treated for 24h with 30 mMN4Py and the percentage of late
apoptotic/necrotic cells (PI positivity) was determined by FACS analysis. Each value shows the mean ± SEM of at least three independent
experiments. *p< 0.05, ***p< 0.001.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 5 9e1 2 7 31268siRNA. In this time frame, PARP inhibitors could only slightly
affect metabolic activity (up to 17% reduction compared to
untreated cells) when combined with NRF2 inhibition in
BRCA1 knockdown A2780 cells (Figure 6A). To study the
long term effects of PARP inhibitors in combination with
NRF2 inhibition, first a doseeresponse curve was obtained
to determine the lowest effective concentration of PARP in-
hibitor in A2780 cells with NRF2 and BRCA1 knockdown:
1 mM olaparib was chosen for subsequent colony forming as-
says (CFA) (Figure 6B). Next, it was confirmed that olaparib
treatment, independent of Nrf2 expression, specifically
affected the colony forming potential of BRCA1 knockdown
and not of wild-type cells (Figure 6B); PARP inhibitor treat-
ment reduced the colony forming potential of BRCA1 knock-
down A2780 cells by 62% compared to untreated, while no
effect was observed for BRCA1 wildtype A2780 cells. BRCA1can directly bind Nrf2, thereby interfere with Keap1 binding,
and enhance the stability and activation of Nrf2 (Gorrini
et al., 2013a). Therefore, BRCA1 inhibition might further
inhibit the activity of Nrf2, and this could translate to a
greater reduction in colony forming potential. Despite this,
inhibition of NRF2 alone reduced the colony forming poten-
tial to the same extent in wild-type (79%) and BRCA1 knock-
down (76%) A2780 cells. In contrast, in healthy ovarian cells
(OSE-C2 cells) no effect on cell growth was observed upon in-
hibition of NRF2 (Suppl. Figure 4B), which reveals the poten-
tial therapeutic window for NRF2 inhibition treatment.
Interestingly, in BRCA1 knockdown A2780 cells, the combina-
tion of 1 mM olaparib and ATF-induced NRF2 inhibition
almost completely diminished the colony forming potential
(90% versus 62% without NRF2 inhibition). This data opens
up the possibility to further increase the therapeutic window
Figure 6 e Downregulation of NRF2 improves the cytotoxic effect of PARP inhibitors in BRCA1 knockdown A2780 ovarian cancer cells. (A)
A2780 cells with (OX2-SKD) or without (empty) ATF-mediated NRF2 downregulation, were transfected with BRCA1 siRNA or RLUC control
siRNA. After 3 days, 1 mM or 5 mM olaparib (PARP inhibitor) or 0.1% DMSO treatment was started. 24 h later, metabolic activity was measured
by the MTS assay. (B) After 24 treatment with either 1 mM olaparib or 0.1% DMSO, cells were seeded for the colony forming assay and colony
formation was determined 6e7 days later. (C) After 24 h treatment, the percentage of cells with increased dsDNA breaks (gH2AX positive) was
determined. *p< 0.05; **p< 0.01; ***p< 0.001.
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apy with PARP inhibitors.
In order to gain a better understanding of the mechanism
by which the PARP-1 inhibitor/NRF2 inhibition combination
therapy in BRCA1 knockdown ovarian cancer cells acts, the ef-
fect of BRCA1 knockdown and 1 mM olaparib on ROS produc-
tion was determined. Neither 1 mM olaparib, nor BRCA1
knockdown (or the combination of both) influenced ROS levels
(Suppl. Figure 7). Inhibition of NRF2 is expected to sensitize
cells toward ROS-induced DNA damage, which is mainly
repaired by BER (Mitra et al., 2001). As PARP inhibitors block
BER, ROS-induced DNA damage is expected to accumulate
(Banerjee and Kaye, 2011; Fong et al., 2009). Upon cell division,
these ssDNA breaks become dsDNA breaks. As BRCA1
impaired cells are unable to repair this damage, colony form-
ing potential is expected to be reduced the most in these cells.
Indeed, treatment of BRCA1 knockdown A2780 cells with 1 mM
olaparib resulted in a 2.2-fold increase in dsDNA breaks
compared to wild-type (Figure 6C). The amount of dsDNAbreaks even further increased up to 3.3-fold compared to
wild-type when NRF2 was inhibited in these cells. Without
knockdown of BRCA1, inhibition of NRF2 did not increase the
formation of dsDNA breaks, highlighting the selectivity of
this combination treatment (Figures 6C and 7).4. Discussion
In this study, NRF2 targeting ZFP-ATFs that are uniquely
suited to study the dual role of Nrf2 in ovarian carcinogenesis,
were constructed and validated. By the use of these NRF2 tar-
geting ATFs, a chemopreventive role of Nrf2 in healthy cells
was confirmed, whereas inhibition of Nrf2 had anti-
carcinogenic effects in malignant cells. With respect to the
chemopreventive function of Nrf2, ATF-induced upregulation
of NRF2 was shown to increase the expression of genes
involved in the protection against ROS-induced damage,
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Figure 7 e Hypothesis enhanced cytotoxic effect of combination therapy (PARP inhibitors and NRF2 inhibition) in BRCA1 mutant cancers.
ATF-mediated (OX2-SKD) repression of NRF2 results in downregulation of downstream target genes involved in the protection against ROS.
This results in enhanced sensitivity toward ROS-induced DNA and protein damage. BER (base excision repair) is mainly involved in the repair of
ROS-induced DNA damage. When PARP inhibitors inhibit this DNA repair pathway, the ROS-induced ssDNA breaks will turn into dsDNA
breaks upon cell division. In normal, non-BRCA1 defective cells, dsDNA breaks will be repaired by the error-free HR (homologous
recombination) DNA repair pathway. In contrast, in malignant, BRCA1 defective cells, dsDNA breaks cannot be repaired by HR, and therefore,
the more error-prone NHEJ (non-homologous end joining) DNA repair pathway will take over. The end-result is genomic instability and this will
induce cell death.
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protection against ROS-induced cell death in healthy ovarian
epithelial cells. With respect to the anti-carcinogenic effects
of Nrf2 inhibition, it was revealed that ATF-induced downre-
gulation ofNRF2 resulted in an almost 80% reduction of colony
forming potential in malignant ovarian epithelial cells. Inter-
estingly, specifically in BRCA1 knockdown ovarian cancer
cells, the effect of NRF2 inhibition on colony forming potential
could be even further improved by co-treating with PARP in-
hibitors: the colony forming potential was almost complete
halted.
The rationale behind ROS-targeted therapies, like inhibi-
tion of Nrf2, is based on the existence of a therapeutic window
as healthy cells have a lower baseline level of ROS compared
to cancer cells (Gorrini et al., 2013b). Here, it was confirmed
that malignant (A2780) versus healthy (OSE-C2) ovarian cells
exhibit higher levels of ROS production. Therefore, to main-
tain redox balance, cancer cells are more dependent on ROS
protective and neutralizing signaling, including Nrf2
signaling. Translated to our study, this would imply that expo-
sure to ROS in combination with ATF-mediated NRF2 inhibi-
tion, would result in a stronger increase in cell death in themalignant (A2780) compared to healthy (OSE-C2) ovarian cells,
which indeed was observed. However, despite specifically
increasing sensitivity toward ROS-induced cell death inmalig-
nant A2780 cells uponNRF2 downregulation, the reached level
of cell death was comparable to that of healthy OSE-C2 cells.
This highlights the importance of a combination therapy
that preferentially hits the tumor cells for further improve-
ment in efficacy of Nrf2 inhibition in cancer.
We hypothesized that PARP inhibitor treatment could
improve the therapeutic window of Nrf2 inhibition (Rouleau
et al., 2010) specifically in BRCA1 mutant cancers, without
acquiring the serious side-effects of chemotherapy or radia-
tion (Cao et al., 2012; Kim et al., 2014). In line with literature
(Fong et al., 2009, 2010; Tutt et al., 2010), the PARP inhibitor ola-
parib could only affect the colony forming potential of BRCA1
knockdown and not BRCA1 wt cells (independent of their Nrf2
status). Therefore, based on literature and our own data,
healthy cells, which are BRCA1 wt, are not expected to be
affected by PARP inhibition. BRCA1 siRNA enabled us to study
the effect of BRCA1 expression in the same background. Here,
it was shown that specifically in BRCA1 knockdown and not
BRCA1 wt cells, the combination of PARP inhibitors and
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this translated to an almost complete inability of the cells to
form colonies. However, likely, also other unknown interac-
tions have contributed to this effect, for example, via PARP-1
its potential to affect transcription and chromatin modifica-
tions (Kim et al., 2005; Kraus and Lis, 2003). This successful
combination of Nrf2 inhibition with PARP inhibitors opens
up opportunities for a therapy in which the efficacy of Nrf2 in-
hibition can be increased without increasing the adverse ef-
fects of previous combinations with chemotherapy or
radiation (Cao et al., 2012; Kim et al., 2014). Interestingly,
recently, it was discovered that inhibition of the transcrip-
tional, but not the enzymatic activity of PARP-1, can inhibit
the activity of PARP-1 in serving as a transcriptional coactiva-
tor of Nrf2. As a transcriptional coactivator, PARP-1 can stim-
ulate the transcriptional activity of Nrf2 by enhancing the
interaction among Nrf2, MafG, and the ARE (Wu et al., 2014).
As such, it can be hypothesized that in addition to inhibiting
the enzymatic activity of PARP-1 by PARP inhibitors, inhibition
of PARP-1 expressionwould have beneficial effectswhen com-
bined with Nrf2 inhibition. However, inhibiting all functions
of PARP-1 will probably also increase the adverse effects.
Exposure to oxidative stress can damage all kinds of bio-
molecules, such as proteins. Accumulation of damaged pro-
teins can activate the ER UPR (Walter and Ron, 2011). One of
the main activators of the ER UPR, PERK, has been shown to
activate Nrf2 via site-specific phosphorylation (Cullinan
et al., 2003). However, the other way around, it is currently un-
knownwhether Nrf2 can activate the ER UPR. Here, we gained
the first insights into the capability of Nrf2 to (in)directly acti-
vate genes involved in the ER UPR; Upon ATF-induced NRF2-
expression in OSE-C2 cells, a similar expression pattern of
ER UPR genes was observed as has been seen before in low
ER stress adapted cells (Rutkowski et al., 2006). In these low
ER stress adapted cells, an attenuation of the activation of
the threemain activators (IRE1, PERK and ATF6) was observed,
whereas proteins such as Bip/GRP78 and p58IPKwere kept sta-
bly activated at a low level. This resulted in an adaptive rather
than a pro-apoptotic ER stress response: cells did not undergo
apoptosis, remained their proliferative capacity despite ER
UPR activation and became desensitized by ROS-induced
stress. As our ATF-induced NRF2-expression OSE-C2 cells
showed a similar response and became desensitized to ROS-
induced stress, we assumed these cells had activated an adap-
tive rather than a pro-apoptotic ER stress response. As protein
homeostasis is strongly influenced by vitagenes, of which
several are activated by Nrf2 (Calabrese et al., 2010), and is
closely linked with health and life span of the organism
(Calabrese et al., 2010), activation of the adaptive ER UPR
response either directly by Nrf2 or indirectly via induction of
vitagenes would be a new mechanism in which Nrf2 could
stimulate longevity and cancer protection. Despite the
inability of OX2-SKD to downregulate (known) Nrf2 down-
stream genes, a trend towards inhibition of these downstream
genes was seen. Therefore, it was unlikely that these findings
could be contributed to the viral transduction, the expression
of a zinc finger protein or off-target effects of OX5-SKD.
Remarkably,NRF2 cDNA did not activate ER UPR to a higher
extent than the ATFOX5-SKD, despite being able to upregulate
NRF2 mRNA more than 10 fold higher compared to OX5-SKD.Although unexpected, Nrf2 might be involved in an adaptive
rather than a pro-apoptotic ER stress response: To prevent
overactivation of the ER stress response, and as such prevent
a pro-apototic ER stress response, the activation of ER UPR
genes by Nrf2 should only occur to a certain extent. It can be
envisioned that simultaneously with Nrf2-induced ER UPR
activation other proteins are counteracting this process, and
as such prevent overactivation of the ER UPR genes. This
would explain that independent of the level of Nrf2 activation,
ER UPR genes are activated to about the same extent.
The KRAB domain in SKD is a transcriptional repressor
which has been frequently fused to ZFPs to downregulate
endogenous gene expression (Huisman et al., 2013; Sera,
2009; Stolzenburg et al., 2012). Surprisingly, in our study,
ATF OX5-SKD resulted in increased expression of NRF2.
KRAB (co-factor)-mediated transcriptional activation has
been seen before in specific cases for naturally occuring
KRAB-containing ZFPs (Chang et al., 1998; Rambaud et al.,
2009; Rooney and Calame, 2001). Genome-wide ChIP-seq anal-
ysis combined with RNA-seq expression analysis revealed re-
lations between binding events and expressional changes for
an engineered ZF-SKD fusion protein (Grimmer et al., 2014).
The ATF binding translated to expression changes in only a
minority (w3%) of the bound regions, of which about one-
third was upregulated. Previously, another engineered ZFP
fused to SKD had been described to induce upregulation of
its target gene OCT4 (Juarez-Moreno et al., 2013). Interestingly,
in this study no effect on OCT4 expression was observed with
the ZFP fused to the transcriptional activator VP64, which is in
contrast to our data obtained with the OX5 ZFP. The opposite
effects of OX2 and OX5 ZFP when fused to VP64 compared to
SKD were confirmed by a NRF2-promoter luciferase reporter,
suggesting a direct effect on the NRF2 promoter. Interestingly,
the binding of transcription factor YY2, a close-relative of YY1
with both activation and repression domains (Nguyen et al.,
2004), partly overlaps with the OX5 ZFP binding region in the
NRF2 promoter. As the function of YY2 might be (in)directly
affected by OX5-SKD, this could provide an explanation for
our findings. Direct binding competition of the ZFP OX5 with
YY2 could be excluded, as OX5-NoED did not have any effect
on NRF2 expression. The effector domain, however, could
attract other proteins that affect the function of YY2 as shown
before for its close-relative YY1 (Yao et al., 2001).
In light of current literature, our results underline Nrf2 as a
promising chemopreventive or therapeutic target in (ovarian)
carcinogenesis. However, caution should be taken as the func-
tion of Nrf2 is context dependent (Sporn and Liby, 2012). To
exploit Nrf2 inhibition as anti-cancer treatment, it is essential
to prevent a pro-carcinogenic outcome in normal cells. There-
fore, the therapeutic window of Nrf2 inhibition should be
further broadened by combining Nrf2 inhibition with other
treatments, such as was studied here with PARP inhibitor
treatment. The main advantage of a combination with PARP
inhibitor treatment over the combination with radiation or
chemotherapy, is the fact that severe side-effects are not ex-
pected (Liu et al., 2014). We speculate that this combination
therapy of PARP inhibitors with Nrf2 inhibition is not only
effective in BRCA1 defective cells (as shown in this study),
but can also be translated to all “BRCAness” tumors. In conclu-
sion, as hyperactivation of Nrf2 is a common phenomenon in
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 5 9e1 2 7 31272cancer (Bauer et al., 2013; Jiang et al., 2010; Stacy et al., 2006;
Wang et al., 2010), Nrf2 can be a potent target to combat not
only ovarian, but also other cancer types.Conflict of interest
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